From: Relationship of cell-free urine MicroRNA with lupus nephritis in children
Features | n of N (%) | Mean (SD) | |
---|---|---|---|
Lupus patients Controls | Lupus Nephritis (LN),n, age (years) | 14 18.33 ± 3.77 | |
SLE without LN,n, age (years) | 10 17.40 ± 2.59 | ||
Fibromyalgia | 5 | ||
Juvenile Idiopathic Arthritis | 5 | ||
Females | 19 (79.1 %) | ||
Race | Black | 13 (54.1 %) | |
White | 8 (33.4 %) | ||
Other° | 3 (12.5 %) | ||
Medications (SLE patients) | Oral prednisone (mg/day) | 24 (100 %) | 26.1 (18.4) |
Mycophenolate mofetil | 10 (41.7 %) | ||
Azathioprine | 1 (4.1 %) | ||
Cyclophosphamide | 10 (41.7 %) | ||
Diuretics | 4 (16.6 %) | ||
Angiotensin system blocking drug | 12 (50 %) | ||
LN Status (n = 14) | GFR£ < 60 ml/min/m2 | 3 (21.4 %) | |
Protein:creatinine ratio > 0.5 | 11 (78.6 %) | ||
Renal SLEDAI* score | 5.6 (6.19) | ||
Renal BILAG score | 4.8 (4.54) | ||
Class 2 | 4 (28.6 %) | ||
ISN/RPS¶ Class 3 | 2 (14.3 %) | ||
Class 4 | 7 (50 %) | ||
Class 5 | 1 (7.1 %) | ||
SLE Status (n = 24) | Complement C3 low | 9 (37.5 %) | |
Complement C4 low | 16 (66.7 %) | ||
Presence of anti-dsDNA antibodies | 18 (75 %) |